Therapeutic Vaccine Strategies against Human Papillomavirus
High-risk types of human papillomavirus (HPV) cause over 500,000 cervical, anogenital and oropharyngeal cancer cases per year. The transforming potential of HPVs is mediated by viral oncoproteins. These are essential for the induction and maintenance of the malignant phenotype. Thus, HPV-mediated ma...
Main Authors: | Hadeel Khallouf, Agnieszka K. Grabowska, Angelika B. Riemer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-06-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-393X/2/2/422 |
Similar Items
-
Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
by: Supitcha Kamolratanakul, et al.
Published: (2021-11-01) -
Nucleic acid vaccines for human papillomavirus; prevention or treatment
by: Solmaz Moniri Javadhesari, et al.
Published: (2019-09-01) -
Recent Developments in Human Papillomavirus (HPV) Vaccinology
by: Anna-Lise Williamson
Published: (2023-06-01) -
Awareness regarding and vaccines acceptability of human papillomavirus among parents of middle school students in Zunyi, Southwest China
by: Yan Xie, et al.
Published: (2021-11-01) -
Cervical Cancer and Human Papillomavirus Awareness among Women in Saudi Arabia
by: Khalid Akkour, et al.
Published: (2021-12-01)